AYBINTIO

Approval Id: bedc5ca6ddfb2ddf
Drug Approval Canada Name: AYBINTIO
Product Name: AYBINTIO
Status: Marketed
Status Date: 2022-06-27
Original Market Date: 2022-06-27
Din: 02522837
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Prescription Recommended , Schedule D
Ahfs: 10:00.00
Atc Original: L01FG01 BEVACIZUMAB
Atc Name: l 01 fg 01
Aig Number: 0151381001
Company Name: Samsung Bioepis Co., Ltd.
Company Address: 76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path: /organization/samsung-bioepis-co-ltd

BEVACIZUMAB

400 MG / 16 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

bedc5ca6ddfb2ddf

Type

Standard